EUPRAXIA PHARMACEUTICALS INC.
EPRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EPRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to develop EP-104GI, a long-acting injectable for eosinophilic esophagitis (EoE), with Phase 2b topline data expected in H2 2026.
Key risk: Single product dependency
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 1 clinical trial · 2 catalysts for EUPRAXIA PHARMACEUTICALS INC..
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to develop EP-104GI, a long-acting injectable for eosinophilic esophagitis (EoE), with Phase 2b topline data expected in H2 2026.
- Cash and equivalents of $80.6M as of 2025-12-31 [sec].
- Phase 2b (RESOLVE trial) topline data for EP-104GI expected in H2 2026 [news · 2025-08-12].
- Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI in Phase 1b/2a [news · 2025-11-04].
- Completed $80.5 million public offering in 2025, with cash runway into first half of 2028 [news · 2025-11-04].
- New data presented at Digestive Disease Week (DDW) 2026 demonstrating improvement of fibrosis and inflammation after a single EP-104GI dose [news · 2026-08-11].
What works
- Proprietary DiffuSphere™ platform enables local, controlled drug delivery, potentially improving safety and efficacy [news · 2025-07-22].
- Phase 1b/2a data showed durable responses out to 52 weeks after a single injection, suggesting a favorable dosing profile [news · 2025-11-04].
- Cash runway into H1 2028 provides funding through key Phase 2b readout and beyond [news · 2025-11-04].
- Strengthened executive team and board to support late-stage development and commercialization [news · 2026-08-11].
What to weigh
- No approved products or revenue; net loss of $38.6M for FY 2025 [sec].
- Phase 2b topline data not expected until H2 2026, with no guarantee of success [news · 2025-08-12].
- Relies on a single lead candidate (EP-104GI), creating concentration risk [news · 2025-11-04].
- Accumulated deficit and ongoing R&D spending may require future financing beyond current cash runway [sec].
From the filings
Quoted directly from source documents.
Phase 2b topline data expected in H2 2026
“topline data expected in H2 2026”
Catalysts · August 12, 2025
Durable responses out to 52 weeks after a single treatment
“Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI”
News · November 4, 2025
Completed $80.5 million public offering
“Completed $80.5 million public offering supported by leading life science investors”
News · November 4, 2025
Catalyst timeline
- 2026-09-30 · Phase2_Topline · ep-104gi — Phase 2 Readout: ep-104gi — Topline data from the Phase 2b RESOLVE trial for EP-104GI in eosinophilic esophagitis is expected by Q3 2026.
- 2026-12-31 · Phase2_Topline · ep-104gi — Phase 2 Readout: ep-104gi — Topline data from the Phase 2b RESOLVE trial for EP-104GI in eosinophilic esophagitis is expected in H2 2026.
Risks & what to watch (4)›
Key risks
- Single product dependency — EP-104GI is the only clinical-stage candidate; failure would leave pipeline empty [news · 2025-11-04].
- No revenue or profitability — Net loss of $38.6M in FY 2025; no approved products generating revenue [sec].
- Clinical trial uncertainty — Phase 2b results not expected until H2 2026; efficacy/safety unproven [news · 2025-08-12].
- Financing risk — Cash runway into H1 2028 may require additional capital if milestones delayed [news · 2025-11-04].
What to watch
- Phase 2b topline data for EP-104GI in EoE, expected H2 2026 [news · 2025-08-12].
- Additional data from cohorts 5–8 of Phase 1b/2a, expected October 2025 [news · 2025-08-12].
- Cash burn rate and any future financing activities [sec].
- Regulatory interactions and potential for accelerated approval pathways [news · 2025-11-04].
Sources: Catalysts · News · SEC filings · Generated August 21, 2026 · How we verify sources →
Run EUPRAXIA PHARMACEUTICALS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available EUPRAXIA PHARMACEUTICALS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
8.6 months
D/E 0.07 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~31d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
49
Total value held
$97.9M
| Holder | Shares | Value |
|---|---|---|
| affinity asset advisors, llc | 1,589,005 | $11.5M |
| balyasny asset management l.p. | 1,350,000 | $9.8M |
| great point partners llc | 1,200,000 | $8.7M |
| scotia capital inc. | 1,342,178 | $7.2M |
| woodline partners lp | 881,102 | $6.4M |
| redmile group, llc | 700,000 | $5.1M |
| rubric capital management lp | 691,170 | $5.0M |
| squadron capital management llc | 680,000 | $4.9M |
| ally bridge group (ny) llc | 660,375 | $4.8M |
| pfm health sciences, lp | 540,871 | $3.9M |
Showing top 10 of 49 institutional holders of EUPRAXIA PHARMACEUTICALS INC.. Open the full 13F history after sign-in.
Short Interest
- % of float
- -
- Days to cover
- —
- Shares short
- -
- Daily short volume (Jun 4, 2026)
- 25.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EPRX short interestFrequently asked questions
What is the AI investment thesis for EUPRAXIA PHARMACEUTICALS INC.?
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to develop EP-104GI, a long-acting injectable for eosinophilic esophagitis (EoE), with Phase 2b topline data expected in H2 2026.
What is EUPRAXIA PHARMACEUTICALS INC.'s next catalyst?
EUPRAXIA PHARMACEUTICALS INC.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: ep-104gi" — expected September 30, 2026.
Who is the CEO of EUPRAXIA PHARMACEUTICALS INC.?
Dr. James A. Helliwell FRCPC, M.D. is the chief executive officer of EUPRAXIA PHARMACEUTICALS INC. (EPRX).
Where is EUPRAXIA PHARMACEUTICALS INC. headquartered?
EUPRAXIA PHARMACEUTICALS INC. (EPRX) is headquartered in Victoria, BC, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.